KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Best Workplace in Switzerland by Great Placed to Work® for fourth consecutive year
Names New Chief Business Officer
Best Workplace in Switzerland by Great Placed to Work® for third consecutive year
Names New Chief Executive Officer
Expands scientific and operational leadership teams
Named among “Best Workplaces in Switzerland” for second consecutive year
Fifth SUREtechnology Platform™-generated product receives market approval
Biosimilar becomes sixth SUREtechnology Platform™-generated marketed product
Names Chief Financial Officer
Achieves 100th commercial license agreement
Invests $2 million in state-of-the art laboratory equipment; expands workforce
Swiss Biotech Association honors Selexis among inaugural Swiss Biotech Success Stories
Earns “Best Companies to Work for in Switzerland 2018” certification
Collaborates with Berkeley Lights to accelerate cell line development with Beacon® optofluidic platform
KBI Biopharma Inc. and Selexis form joint Scientific Advisory Board
Opens new world-class laboratory facility and corporate headquarters in Geneva, Switzerland
Acquired by JSR Life Sciences
First Selexis SUREtechnology-generated therapeutic monoclonal antibody approved
Uses next-generation sequencing to fully sequence Selexis-generated research cell banks
Launches SURE CHO-Mplus Libraries™
Sells potential milestone and royalty payments to Ligand Pharmaceuticals
Doubles cell line development laboratory space in Geneva, Switzerland
Completes sequencing of the Selexis SURE CHO-M genome along with scientists at University of Lausanne
Celebrates 10-year anniversary
Launches SUREvariant Screening™
Forms Scientific Advisory Board headed by Sir Gregory Paul Winter, CBE, FRS, FMed Sci
Expands European production and business operations with new facilities and staff
Establishes U.S. subsidiary, Selexis, Inc.
Opens new R&D facility in Plan-les-Ouates, Switzerland
Dr. Fisch wins New Entrepreneurs for Technology and Sciences (NETS) Best Prize
Company co-founded by Dr. Fisch and Prof. Nicolas Mermod, Ph.D., using winning funds from De Vigier Prize
Igor Fisch, Ph.D., wins the De Vigier Prize for the best biotech idea of Y2K
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.